CYP3A4 and CYP3A5 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase.

Humans Pharmacogenetics Cytochrome P-450 CYP3A / genetics Genotype Consensus Pathology, Molecular Pharmacists Pathologists

Journal

The Journal of molecular diagnostics : JMD
ISSN: 1943-7811
Titre abrégé: J Mol Diagn
Pays: United States
ID NLM: 100893612

Informations de publication

Date de publication:
09 2023
Historique:
received: 20 04 2023
revised: 17 05 2023
accepted: 01 06 2023
pmc-release: 01 09 2024
medline: 22 8 2023
pubmed: 8 7 2023
entrez: 7 7 2023
Statut: ppublish

Résumé

The goals of the Association for Molecular Pathology Clinical Practice Committee's Pharmacogenomics (PGx) Working Group are to define the key attributes of pharmacogenetic alleles recommended for clinical testing and a minimum set of variants that should be included in clinical PGx genotyping assays. This document series provides recommendations for a minimum panel of variant alleles (tier 1) and an extended panel of variant alleles (tier 2) that will aid clinical laboratories when designing assays for PGx testing. The Association for Molecular Pathology PGx Working Group considered functional impact of the variant alleles, allele frequencies in multiethnic populations, the availability of reference materials, and other technical considerations for PGx testing when developing these recommendations. The goal of this Working Group is to promote standardization of PGx gene/allele testing across clinical laboratories. This document will focus on clinical CYP3A4 and CYP3A5 PGx testing that may be applied to all CYP3A4- and CYP3A5-related medications. These recommendations are not to be interpreted as prescriptive but to provide a reference guide.

Identifiants

DOI: 10.1016/j.jmoldx.2023.06.008 PMID: 37419245 PMC: PMC10565868
pubmed: 37419245
pii: S1525-1578(23)00136-8
doi: 10.1016/j.jmoldx.2023.06.008
pmc: PMC10565868
pii:
doi:

Substances chimiques

Cytochrome P-450 CYP3A EC 1.14.14.1
CYP3A5 protein, human EC 1.14.14.1
CYP3A4 protein, human EC 1.14.14.55

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

619-629

Subventions

Organisme : NHGRI NIH HHS
ID : U24 HG010615
Pays : United States
Organisme : NHGRI NIH HHS
ID : U24 HG010135
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD055651
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG006487
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG007269
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001427
Pays : United States

Informations de copyright

Copyright © 2023 Association for Molecular Pathology and American Society for Investigative Pathology. All rights reserved.

Références

Genet Med. 2022 Apr;24(4):759-768
pubmed: 35177334
Pharmacogenet Genomics. 2012 Jul;22(7):555-8
pubmed: 22407409
J Mol Diagn. 2021 Sep;23(9):1047-1064
pubmed: 34118403
Clin Pharmacol Ther. 2021 Jul;110(1):169-178
pubmed: 33452682
Clin Pharmacol Ther. 2015 Jul;98(1):19-24
pubmed: 25801146
Pharmacogenetics. 2001 Dec;11(9):773-9
pubmed: 11740341
J Pharmacol Exp Ther. 1994 Jul;270(1):414-23
pubmed: 8035341
Front Psychiatry. 2013 Sep 12;4:102
pubmed: 24062697
Pharmacogenomics J. 2015 Jun;15(3):288-92
pubmed: 25348618
Clin Chem. 2002 Oct;48(10):1668-71
pubmed: 12324482
Front Oncol. 2022 Jan 31;11:809527
pubmed: 35174070
Mol Pharmacol. 2002 Jul;62(1):162-72
pubmed: 12065767
J Mol Diagn. 2016 Jan;18(1):109-23
pubmed: 26621101
J Mol Diagn. 2018 May;20(3):269-276
pubmed: 29474986
Arch Biochem Biophys. 1989 Nov 1;274(2):355-65
pubmed: 2802615
Clin Cancer Res. 2015 Jan 15;21(2):322-8
pubmed: 25398452
Clin Pharmacol Ther. 2021 Sep;110(3):542-545
pubmed: 34091888
Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94
pubmed: 12406645
Clin Pharmacol Ther. 2006 Apr;79(4):339-49
pubmed: 16580902
Clin Pharmacol Ther. 2019 May;105(5):1256-1262
pubmed: 30506572
J Mol Diagn. 2019 Sep;21(5):746-755
pubmed: 31075510
Clin Pharmacol Ther. 2018 Mar;103(3):399-401
pubmed: 29134625
Drug Metab Dispos. 2006 May;34(5):880-6
pubmed: 16467132
Front Genet. 2021 Jul 08;12:711943
pubmed: 34306041
Clin Pharmacokinet. 2019 Oct;58(10):1281-1294
pubmed: 30972694
Arch Pathol Lab Med. 1991 Jun;115(6):607-9
pubmed: 2039345
Front Pharmacol. 2022 Jun 16;13:912618
pubmed: 35784699
Nat Genet. 2001 Apr;27(4):383-91
pubmed: 11279519
Transplant Proc. 1999 Feb-Mar;31(1-2):296-8
pubmed: 10083114
Pharmacogenomics J. 2011 Aug;11(4):274-86
pubmed: 20386561
J Mol Diagn. 2020 Jul;22(7):847-859
pubmed: 32380173
Pediatr Transplant. 2018 Nov;22(7):e13285
pubmed: 30178515
J Mol Diagn. 2023 Sep;25(9):655-664
pubmed: 37354993
Pharmacogenomics. 2013 Jan;14(2):137-49
pubmed: 23327575
Transplant Proc. 2002 Aug;34(5):1836-8
pubmed: 12176596
J Mol Diagn. 2022 Oct;24(10):1051-1063
pubmed: 35931343
Pharmacogenet Genomics. 2016 Jan;26(1):40-3
pubmed: 26488616

Auteurs

Victoria M Pratt (VM)

Pharmacogenomics Working Group of the Clinical Practice Committee, Association for Molecular Pathology, Rockville, Maryland; Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana. Electronic address: vpratt@iu.edu.

Larisa H Cavallari (LH)

Pharmacogenomics Working Group of the Clinical Practice Committee, Association for Molecular Pathology, Rockville, Maryland; Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, University of Florida, Gainesville, Florida.

Makenzie L Fulmer (ML)

Pharmacogenomics Working Group of the Clinical Practice Committee, Association for Molecular Pathology, Rockville, Maryland; Department of Pathology and ARUP Laboratories, University of Utah School of Medicine, Salt Lake City, Utah.

Andrea Gaedigk (A)

Pharmacogenomics Working Group of the Clinical Practice Committee, Association for Molecular Pathology, Rockville, Maryland; Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Research Institute and School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri.

Houda Hachad (H)

Pharmacogenomics Working Group of the Clinical Practice Committee, Association for Molecular Pathology, Rockville, Maryland; Department of Clinical Operations, AccessDx, Houston, Texas.

Yuan Ji (Y)

Pharmacogenomics Working Group of the Clinical Practice Committee, Association for Molecular Pathology, Rockville, Maryland; Department of Pathology and ARUP Laboratories, University of Utah School of Medicine, Salt Lake City, Utah.

Lisa V Kalman (LV)

Pharmacogenomics Working Group of the Clinical Practice Committee, Association for Molecular Pathology, Rockville, Maryland; Division of Laboratory Systems, Centers for Disease Control and Prevention, Atlanta, Georgia.

Reynold C Ly (RC)

Pharmacogenomics Working Group of the Clinical Practice Committee, Association for Molecular Pathology, Rockville, Maryland; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana.

Ann M Moyer (AM)

Pharmacogenomics Working Group of the Clinical Practice Committee, Association for Molecular Pathology, Rockville, Maryland; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

Stuart A Scott (SA)

Pharmacogenomics Working Group of the Clinical Practice Committee, Association for Molecular Pathology, Rockville, Maryland; Department of Pathology, Stanford University, Stanford, California; Clinical Genomics Laboratory, Stanford Medicine, Palo Alto, California.

Ron H N van Schaik (RHN)

Pharmacogenomics Working Group of the Clinical Practice Committee, Association for Molecular Pathology, Rockville, Maryland; Department of Clinical Chemistry/International Federation of Clinical Chemistry and Laboratory Medicine Expert Center Pharmacogenetics, Erasmus MC University Medical Center, Rotterdam, the Netherlands.

Michelle Whirl-Carrillo (M)

Pharmacogenomics Working Group of the Clinical Practice Committee, Association for Molecular Pathology, Rockville, Maryland; Department of Biomedical Data Science, Stanford University, Stanford, California.

Karen E Weck (KE)

Pharmacogenomics Working Group of the Clinical Practice Committee, Association for Molecular Pathology, Rockville, Maryland; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina; Department of Genetics, University of North Carolina, Chapel Hill, North Carolina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › CYP3A4 and CYP3A5 Genotyping Recommendations:...
questionsmedicales.fr › Professions de santé › Pharmacologie › Pharmacogénétique › CYP3A4 and CYP3A5 Genotyping Recommendations:...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Hémoprotéines › Cytochromes › Cytochrome P-450 enzyme system › Famille-3 de cytochromes P450 › Cytochrome P-450 CYP3A › CYP3A4 and CYP3A5 Genotyping Recommendations:...
questionsmedicales.fr › Phénomènes génétiques › Génotype › CYP3A4 and CYP3A5 Genotyping Recommendations:...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Pensée (activité mentale) › Prise de décision › Consensus › CYP3A4 and CYP3A5 Genotyping Recommendations:...
questionsmedicales.fr › Professions de santé › Médecine › Anatomopathologie › Anatomopathologie moléculaire › CYP3A4 and CYP3A5 Genotyping Recommendations:...
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Personnel de santé › Pharmaciens › CYP3A4 and CYP3A5 Genotyping Recommendations:...
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Personnel de santé › Médecins › Anatomopathologistes › CYP3A4 and CYP3A5 Genotyping Recommendations:...